Patients gave blood serum samples prior to the treatment in 1992 and one year products later for in 1993. They were immunoassayed for specific IgE antibodies using a chemi-luminescent technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE levels to one-year. For the seasonal allergens reported, the active group (n=34) had on average a greater reduction in IgE than the placebo group (n=33).7 On August 14, 1996 representatives of Broncorp, Inc. met with the Division Director, Dr. John Jenkins, hypertension and 14 other FDA officials of the Pulmonary Division at a PreNDA meeting. Dr. Mansfield made a presentation on the 1995 study data (n=165) from Oregon, Washington and Idaho. He noted that together the products data failed to show statistical for superiority of vitamin B12 on the primary endpoint. He noted that in Washington hypertension and Idaho, during the later part of the study, products there was a drop in the pollen counts and marked improvements for in symptoms hypertension in both the vitamin B12 and placebo groups. (This made a therapeutic benefit of the B12 treatment difficult to demonstrate.) But that the pollen counts in Oregon products remained higher throughout for the study and that the data from Oregon showed a significant difference between the active and placebo groups.8

Jay M. Symptoms not very bad. Karl L. My hypertension congestion allergies did seem to get better after several days...Marsha R. I had some better days. Erin products C. I believe it helped to a certain extent. William R. Improved after 3 days. Nancy C. On day 16 I felt so much better, by day 30 allergies continued to be improved. Angel C. Background of Cyanocobalamin Treatment in Allergic Disease MECHANISM OF ACTION: Vitamin B12 is essential to cell growth and cell division. B12 is the only known molecule in the human body uses with the element cobalt. The unique properties for of cobalt permit a chemical reaction that produces the rungs of the DNA ladder. These rungs are called nucleotides. For any human cell to divide, it must copy its own DNA. For this replication to occur, new rungs of the ladder must be provided with the help of B12.

Studies indicate that hypertension ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic disease, perhaps because once ingested, they are directly metabolized in the liver. When B12 is delivered via injection or lozenge products it passes throughout for the bloodstream before arriving at the liver. It is during this first pass in its native form that it is believed to exert its therapeutic effect. CLINICAL RESEARCH: "The World Health Organization (WHO) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, eczema, dermatitis (contact and atopic)...allergic and migraine headache...as diseases in which IgE-mediated allergy may be involved."1 In 1988, asthma and allergic hypertension and products rhinitis subjects were treated with B12. Total IgE, specific IgE and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies at two sites in Riverside County, CA in 1989. Sixteen of the 17 subjects had lowered for IgE levels from Day 0 to Day hypertension 30.3